News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Invex Therapeutics.
RELATED STOCKHEAD STORIES
ASX Health Stocks: Multimillion dollar contracts for 1ST and Austco; Invex shuts down clinical trial
News
CLOSING BELL: Orexplore’s +150pc ray of BHP deal sunshine pours light on a dismal day
News
Top 10 at 10: Super gold hits, lithium nearology, and a potential niobium discovery
News
Rise and Shine: Everything you need to know before the ASX opens
News
ASX Small Caps and IPO Weekly Wrap: ASX falls 1.1% for the week, an ass-kicking we probably didn’t deserve
News
Closing Bell: ASX runs out of puff, closes down 1.5% as energy sector weighs on markets
News
In Case You Missed It: Biotech stands out in a sea of lithium
News
ASX Small Caps Lunch Wrap: Who else is in desperate need of some eyebleach today?
Health & Biotech
ASX Health Stocks: Invex granted orphan drug designation in Europe; Resonance has a new CEO
Top 10 at 10: Delta Lithium soars on highest tenor intercept to date at Yinnetharra
News
Market Highlights: Wall Street rebounds, Tesla downgraded, and India’s climb on global ladder
News
Market Highlights: Tesla crashes 10pc, SpaceX rocket explodes, and 5 ASX small caps to watch on Friday
Health & Biotech
ASX Health Stocks: Healius gets takeover offer from company less than half its size
News
Market Highlights: A ‘sad’ day in Europe, ASX to shed 1pc more, and 5 small caps to watch today
Health & Biotech
The chances of Phase 3 success, and the ASX health stocks that are close to a home run
Health & Biotech
ASX Health Stocks: Zelira to test its own drug against a Big Pharma’s multi-billion dollar revenue star
Health & Biotech
